VISTAGEN THERAPEUTICS, INC. (VTGN) Operating cash flow 2017–2026
VISTAGEN THERAPEUTICS, INC. (VTGN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$66.4MFY2026 · since FY2017: -$7.3M → -$66.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$66.4M | -57.8% |
| FY2025 | -$42.1M | -63.1% |
| FY2024 | -$25.8M | +48.1% |
| FY2023 | -$49.7M | -9.9% |
| FY2022 | -$45.3M | -274.8% |
| FY2021 | -$12.1M | +23.4% |
| FY2020 | -$15.8M | -8.5% |
| FY2019 | -$14.5M | -60.4% |
| FY2018 | -$9.1M | -24.7% |
| FY2017 | -$7.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VTGN financial trends
VTGN RevenueVTGN Net incomeVTGN Net marginVTGN Gross profitVTGN Gross marginVTGN Operating incomeVTGN Operating marginVTGN Free cash flowVTGN Capital expendituresVTGN Return on equityVTGN Stock buybacksVTGN Dividends paidVTGN Total assetsVTGN Total liabilitiesVTGN Shareholders’ equityVTGN overview →